Ribas, Antoni

MITF drives endolysosomal biogenesis and potentiates Wnt signaling in melanoma cells

Ploper, D., Taelman, V. F., Robert, L., Perez, B. S., Titz, B., Chen, H.-W., Graeber, T. G., von Euw, E., Ribas, A., & De Robertis, E. M. (2015) · Proceedings of the National Academy of Sciences

Wnt/β-catenin signaling in development and cancerCalcium signaling and nucleotide metabolism

Cited by 228

Overcoming PD-1 Blockade Resistance with CpG-A Toll-Like Receptor 9 Agonist Vidutolimod in Patients with Metastatic Melanoma

Ribas, A., Medina, T., Kirkwood, J. M., Zakharia, Y., Gonzalez, R., Davar, D., Chmielowski, B., Campbell, K. M., Bao, R., Kelley, H., et al. (2021) · Cancer Discovery

Cancer Immunotherapy and BiomarkersImmunotherapy and Immune Responses

Cited by 180

Raman-guided subcellular pharmaco-metabolomics for metastatic melanoma cells

Du, J., Su, Y., Qian, C., Yuan, D., Miao, K., Lee, D., Ng, A. H. C., Wijker, R. S., Ribas, A., Levine, R. D., et al. (2020) · Nature Communications

Spectroscopy Techniques in Biomedical and Chemical ResearchCancer, Lipids, and Metabolism

Cited by 171

CTLA4 blockade induces frequent tumor infiltration by activated lymphocytes regardless of clinical responses in humans

Huang, R. R., Jalil, J., Economou, J. S., Chmielowski, B., Koya, R. C., Mok, S., Sazegar, H., Seja, E., Villanueva, A., Gomez-Navarro, J., et al. (2011) · Clinical Cancer Research

Cancer Immunotherapy and BiomarkersImmunotherapy and Immune Responses

Cited by 157

Overcoming Genetically Based Resistance Mechanisms to PD-1 Blockade

Torrejon, D. Y., Abril-Rodriguez, G., Champhekar, A. S., Tsoi, J., Campbell, K. M., Kalbasi, A., Parisi, G., Zaretsky, J. M., Garcia-Diaz, A., Puig-Saus, C., et al. (2020) · Cancer Discovery

Cancer Immunotherapy and BiomarkersImmunotherapy and Immune Responses

Cited by 146

Circulating tumour DNA in patients with advanced melanoma treated with dabrafenib or dabrafenib plus trametinib: a clinical validation study

Syeda, M. M., Wiggins, J. M., Corless, B. C., Long, G. V., Flaherty, K. T., Schadendorf, D., Nathan, P. D., Robert, C., Ribas, A., Davies, M. A., et al. (2021) · The Lancet Oncology

Melanoma and MAPK PathwaysCancer Genomics and Diagnostics

Cited by 101

Anti-PD-1 antibody treatment for melanoma

Ribas, A., Kirkwood, J. M., & Flaherty, K. T. (2018) · The Lancet Oncology

Cancer Immunotherapy and BiomarkersCutaneous Melanoma Detection and Management

Cited by 20